Lenvakin 4 mg (Capsule)
Unit Price: ৳ 650.00 (2 x 7: ৳ 9,100.00)
Strip Price: ৳ 4,550.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
- Differentiated Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Carcinoma
Pharmacology
- Kinase inhibitor
- Inhibits VEGF receptors
- Inhibits FGF receptors
- Inhibits PDGFR
- Inhibits KIT and RET
Absorption
Peak plasma concentration occurs from 1 to 4 hours post-dose
Distribution
In vitro binding to human plasma proteins ranged from 98% to 99%
Metabolism
- Mainly through enzymatic and non-enzymatic processes
- CYP3A and aldehyde oxidase
Elimination
- Approximately 64% elimination in feces
- Approximately 25% elimination in urine
- Terminal elimination half-life approximately 28 hours
Dosage
- Differentiated Thyroid Cancer (DTC): 24 mg orally once daily
- Renal Cell Carcinoma (RCC): 18 mg in combination with 5 mg Everolimus orally once daily
- Hepatocellular Carcinoma (HCC): 12 mg for patients greater than or equal to 60 kg, 8 mg for patients less than 60 kg orally once daily
- Endometrial Carcinoma: 20 mg orally once daily, in combination with Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks
Administration
Capsules can be swallowed whole or dissolved in liquid
Interaction
Avoid coadministration with drugs that prolong the QT interval
Contraindications
Known hypersensitivity to Lenvatinib or any component of the formulation
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Proteinuria
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT Interval Prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Risk of embryo-fetal harm
- Females of reproductive potential should use effective contraception
- Discontinue breastfeeding during treatment
Precautions & Warnings
- Hypertension control
- Cardiac Dysfunction monitoring
- Arterial Thromboembolic Events management
- Hepatotoxicity monitoring
- Renal Failure monitoring
- Proteinuria monitoring
- Diarrhea management
- Fistula Formation and Gastrointestinal Perforation considerations
- QT Interval Prolongation monitoring
- Hypocalcemia management
- Reversible Posterior Leukoencephalopathy Syndrome considerations
- Hemorrhagic Events risk assessment
- Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction monitoring
- Wound Healing Complications management
Use in Special Populations
- Dosage Modifications for Severe Renal Impairment: Dose reduction for DTC, RCC, or endometrial carcinoma
- Dosage Modifications for Severe Hepatic Impairment: Dose reduction for DTC, RCC, or endometrial carcinoma
- Pediatric Use: Safety and effectiveness in pediatric patients not established
Overdose Effects
Not expected to be dialyzable. Death due to multiorgan dysfunction occurred with a single dose of Lenvakin 120 mg
Storage Conditions
Store below 30°C in a dry place, protect from light, keep out of the reach of children